After holding out, bluebird bio investors get on board with sale to Carlyle, SK Capital
Holding out for a better upfront deal has paid off for bluebird bio investors to the tune of an additional $2.00 per share. Private equity firms Carlyle and SK Capital expect to complete the acquisition of bluebird on Monday. With an amended agreement—bumping up their per-share offer from $3.00 to $5.00—Carlyle and SK have convinced enough investors to sell their shares to complete the transaction.
Holding out for a better upfront deal has paid off for bluebird bio investors to the tune of an additional $2.00 per share. Private equity firms Carlyle and SK Capital expect to complete the acquisition of bluebird on Monday. With an amended agreement—bumping up their per-share offer from $3.00 to $5.00—Carlyle and SK have convinced enough investors to sell their shares to complete the transaction.
